WHEL-C-095 · Moderate evidence · 7/10

anti-androgens for PCOS

A systematic review and meta-analysis of RCTs found anti-androgens may mitigate hyperandrogenism-related symptoms of PCOS but are not preferred over combined oral contraceptives except when COCPs are contraindicated, poorly tolerated, or inadequately effective.

Origin · Existing drug · repurposing candidatePathway · 505(b)(2) · existing active ingredient, new indicationEvidence arm · Direct researchEvidence supports

How to read thisThe summary above and the proposed mechanism are generated by the model from the sources it ingested, and are written as the model’s reasoning rather than established fact. Any figure quoted from MATRIX is a model-derived association score, not a clinical measurement. How far the published record backs this pair is carried by the score’s own rigor dimension and traced to verbatim sources at the foot of the page.

Hypothesized mechanism

Anti-androgens reduce androgen activity, thereby mitigating hyperandrogenism-driven symptoms such as hirsutism in PCOS.

This is the model’s proposed mechanism from the sources on file, not a demonstrated causal pathway. How well the published record supports it is reflected in the rigor and plausibility dimensions of the score, and traced to the verbatim sources at the foot of the page.

How the score was reached, for this pair

The composite score is the sum of five dimensions, each scored 0 to 2 by the model from the evidence on file. Below is the sub-score this specific pair received on each, with what that dimension measures. It scored 7 of 10 overall, a moderate reading, from a direct rated moderate in strength.

The model’s overall reasoning for this pair is the summary at the top of the page, and the mechanism it proposed is in the section above.

Direct research arm · anchors the headline7.0 / 10 · Moderate

Scored for women. Evidence generated in women (female population, ~100% female). (band F1, ×1.00).

Corroboration

All three claims derive from a single systematic review and meta-analysis of randomised controlled trials. Per scoring rules, a single synthesis scores 1 and does not count the pooled trials as independent sources.

1 / 2

Rigor

The source is a systematic review and meta-analysis of randomised controlled trials, the highest rigor tier. This warrants a score of 2.

2 / 2

Specificity

The claims explicitly name both anti-androgens and PCOS/hyperandrogenism-related symptoms. Both the intervention and condition are directly identified.

2 / 2

Plausibility

The claims state anti-androgens mitigate hyperandrogenism-related symptoms, implying an anti-androgen mechanism against androgen-driven symptoms, which is plausible. However, no explicit mechanistic evidence is detailed in the quotes.

1 / 2

Consistency

Claims show a nuanced direction: anti-androgens may help symptoms but are not preferred over COCPs except in specific scenarios. Within this single meta-analysis the findings are coherent, so a neutral score of 1 applies.

1 / 2

How the scoring rubric works, in general →

Layers not covered for this pair

Sex-specific pharmacokineticsNone on file

Not covered for this pair. This layer holds documented sex-specific pharmacokinetics for a limited set of drugs, and this compound is not among them yet. A blank here means the drug is not covered by the layer, not that no sex difference exists.

More on the sex-specific pharmacokinetics layer and its sources →

Cycle-phase dependenceNone on file

Not covered for this pair. The cycle-phase layer is seeded for the strongest-evidence cases so far (PMDD), and this pair is not among them yet. A blank here means the pair is not covered by the layer, not that the effect was found to be phase-independent.

More on the cycle-phase layer and its sources →

Source evidence · what the pipeline ingested

These are the sources the pipeline ingested to detect and score this signal, the published literature the model actually read, each tagged by study type. Where the model combined findings the claim is marked as a synthesis (S), and where the literature disagrees the contradiction is shown (!).

Every source below belongs to this signal’s evidence arm, Direct research. Whel reads each drug-condition pair through four such arms, each held to its own inclusion bar; a signal is surfaced through one of them.

1Anti-androgens and combined oral contraceptive pills (COCPs) may mitigate hyperandrogenism-related symptoms of polycystic ovary syndrome (PCOS) PubMed · PMID 37583655 ↗
2Current evidence does not support the use of anti-androgens preferentially to COCPs to treat hyperandrogenism in PCOS. PubMed · PMID 37583655 ↗
3Anti-androgens could be considered to treat hirsutism in PCOS, where COCPs are contraindicated, poorly tolerated, or present a sub-optimal response after a minimum 6-month period PubMed · PMID 37583655 ↗

These are the verbatim sources the pipeline surfaced and read; they may not be the full published record for a pair, and the score reflects the strength and agreement of the evidence rather than its volume. The strength of these source types is what the rigor dimension of the score reads off. MATRIX, sex-specific pharmacokinetics, and cycle phase are separate layers the pipeline does not ingest, external cross-references reported beside the score, and they link to their own sources in their sections above.

The primary sources and pipelines this evidence is drawn from →

← Back to the full index